Ajinomoto, Astellas Pharma Jointly File Application Seeking Additional Approval for Combination Therapy of FASTIC/STARSIS Tablets, Fast-acting Postprandial Hypoglycemic Agent, with Biguanide.Tokyo, Japan, Jan 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Ajinomoto and Astellas Pharma jointly announced on January 27 that they have filed a supplemental New Drug Application (SNDA SNDA Supplemental New Drug Application SNDA Student National Dental Association SNDA Subordination, Non-Disturbance and Attornment SNDA Singapore Nutrition and Dietectics Association SNDA Southern Nevada Darts Association (Las Vegas, Nevada) ) for FASTIC Tablet/STARSIS Tablet (nateglinide), a fast-acting postprandial postprandial /post·pran·di·al/ (-pran´de-al) occurring after a meal. post·pran·di·al adj. Following a meal, especially dinner. hypoglycemic agent co-developed by the two companies. The two companies expect approval for combination therapy of FASTCI/STARSIS with biguanide Biguanides (ATC A10 BA) form a class of oral antihyperglycemic drugs used for diabetes mellitus or prediabetes treatment. Examples Examples of biguanides:
Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion